Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic B7H3 CAR-γδT Cell Therapy for Advanced Solid Tumors
NCT06825455Phase 1Not yet recruiting
- Sponsor
- Peking University
- Start
- Mar 2025
- Primary completion
- Dec 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of UTAA06 in solid tumor (advanced stage), ovarian cancer and primary peritoneal cancer (PPC) (2 arms), sponsored by Peking University. Primary endpoint: Incidence of Adverse Events at 12 months. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
UTAA06
03
Conditions
solid tumor (advanced stage)ovarian cancerprimary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT06825455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06825455.